LENZ Therapeutics (LENZ) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 12, 2026, with voting available online, by phone, or mail.

• Key proposals include electing three Class II directors and ratifying Ernst & Young LLP as the independent auditor for 2026.

• Only stockholders of record as of April 14, 2026, are entitled to vote.

• The company completed a merger in March 2024, resulting in a new corporate structure and board.

Voting matters and shareholder proposals

• Stockholders will vote on electing three Class II directors for terms expiring in 2029.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 is on the agenda.

• Board recommends voting “FOR” all director nominees and auditor ratification.

• Shareholder proposals for the 2027 meeting must be received by December 29, 2026.

Board of directors and corporate governance

• The board consists of seven directors, six of whom are independent.

• Board is divided into three classes with staggered three-year terms.

• Committees include audit, compensation, and nominating/governance, all composed of independent directors.

• Board leadership roles are separated between the chair and CEO.

• Policies prohibit hedging or pledging of company securities by insiders.